T-cell lymphoma: the CAR-T revolution is coming
In this issue of Blood, Hill et al demonstrate the safety and feasibility of chimeric antigen receptor T (CAR T) cells targeting CD5 in treating patients with relapsed and refractory mature T-cell lymphoma
Authors
- Natalie Sophia Grover (ORCID: https://orcid.org/0000-0002-1346-3157)
- Anne W. Beaven
Institutions
- University of North Carolina at Chapel Hill (US)
Publication Details
- Journal
- UNC Libraries
- Published
- 2025-03-29
- DOI
- https://doi.org/10.17615/5sz1-e525
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00